Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Completed · Not applicable · NCT03241459
Conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
At a glance
- Research payments reported, 2025
- $2,760
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 446
About the trial
- Sponsor
- SurModics, Inc.
- Tested
- Surmodics SurVeil DCB (device), Medtronic IN.PACT Admiral DCB (device)
- Dates
- Started 2017-10-23; completion 2024-09-17
- Results posted
- Yes
To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.
From ClinicalTrials.gov, last updated 2025-03-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Surmodics, Inc. reported $2,760 in research payments for this study in 2025 (1 payments).
Products named: Surveil Drug-Coated Balloon
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $2,760
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.